Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9 - Full Text View

Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) New York State Psychiatric Institute
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000274

Purpose

The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.

Condition	Intervention	Phase
Cocaine-Related Disorders Substance-Related Disorders	Drug: Flupenthixol	Phase II

Drug Information available for:

8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride Haloperidol Haloperidol decanoate Flupenthixol Flupenthixol decanoate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Side effects
Drug use
Psychiatric symptoms
Cocaine craving

Estimated Enrollment:	60
Study Start Date:	March 1997
Estimated Study Completion Date:	May 1999

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000274

Locations


United States, New York
	New York State Psychiatric Institute
	New York, New York, United States, 10032

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

New York State Psychiatric Institute

Investigators


Principal Investigator:	Herbert Kleber, M.D.	New York State Psychiatric Institute

More Information

Study ID Numbers:	NIDA-09236-9, P50-09236-9
First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000274
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Haloperidol

Cocaine-Related Disorders

Flupenthixol

Haloperidol decanoate

Dopamine

Flupenthixol decanoate

Mental Disorders

Substance-Related Disorders

Disorders of Environmental Origin

Cocaine

Additional relevant MeSH terms:

Neurotransmitter Agents

Disease

Tranquilizing Agents

Molecular Mechanisms of Pharmacological Action

Anti-Dyskinesia Agents

Physiological Effects of Drugs

Gastrointestinal Agents

Psychotropic Drugs

Antiemetics

Central Nervous System Depressants

Dopamine Antagonists

Antipsychotic Agents

Pharmacologic Actions

Pathologic Processes

Autonomic Agents

Therapeutic Uses

Dopamine Agents

Peripheral Nervous System Agents

Central Nervous System Agents

ClinicalTrials.gov processed this record on December 03, 2008